Special Issue "Immune Modulating Therapeutics for Cancer Immunotherapy & Vaccination"
Deadline for manuscript submissions: 31 August 2022 | Viewed by 1132
Interests: immunogenic cell death; immunoengineering; chemotherapy; immunotherapy; tumor microenvironment; drug delivery; nanomedicine; bioengineering; biomaterial; liposomes; exsosomes
We are launching an exciting Special Issue on Immune Modulating Therapeutics for Cancer Immunotherapy & Vaccination. This Special Issue aims to collect original research and review articles on recent developments in the rapidly developing immune engineering field, focusing on immune-modulating therapeutics to empower cancer vaccination and immunotherapy. We are pleased to invite you to contribute to one of the broad topics that synergize the focus of this special issue, e.g., ways to increase cancer immunogenicity (with chemotherapeutics, PDT, radiation, or natural products etc.), novel vaccines to establish long-term anti-cancer immunity, strategies to overcome tumor immune suppression, CAR-T/NK therapeutics, novel antibody therapeutics, immune-modulating drug targets and drug discovery, methods to profile patient biopsy for personalized combinational immunotherapy, and other novel interventions, broadly defined. Thank you, and I look forward to receiving your contributions.
Dr. Kuo-Ching Mei
Dr. Tian Xia
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- tumor microenvironment
- immune checkpoint
- cancer vaccine
- immunogenic cell death
- drug delivery
- immune modulation
- cell-based therapy
- immune supression